What is Theravance Biopharma's stock issuance proceeds?

Theravance Biopharma (TBPH) reported stock issuance proceeds of $241K in Q1 2026.

How has Theravance Biopharma's stock issuance proceeds changed year-over-year?

Theravance Biopharma's stock issuance proceeds increased by 1105.0% year-over-year, from $20K to $241K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Theravance Biopharma TBPH Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Zevra Therapeutics, Inc.ZVRA

$752K—

LQD

Liquidia CorporationLQDA

$1.75M+38.6%

United TherapeuticsUTHR

$68.3M+311%

Aurinia PharmaceuticalsAUPH

$713K-92.3%

PrecigenPGEN

$0+100%

Mirum Pharmaceuticals, Inc.MIRM

$10.13M+59.3%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's stock issuance proceeds?: Theravance Biopharma (TBPH) reported stock issuance proceeds of $241K in Q1 2026.
How has Theravance Biopharma's stock issuance proceeds changed year-over-year?: Theravance Biopharma's stock issuance proceeds increased by 1105.0% year-over-year, from $20K to $241K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.